Association between caffeine intake and liver biomarkers in non-alcoholic fatty liver disease
Öz
Purpose: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver enzymes in developed countries. The aim of this study is to examine the effects of caffeine intake on some parameters of liver metabolism in individuals with NAFLD.
Materials and Methods: A total of 20 female and 20 male subjects between the ages of 19 to 64, who were diagnosed with NAFLD, were included in the study. To determine caffeine intake, a specially developed caffeine-food frequency questionnaire was administered by a trained dietitian. Individuals were categorized into 3 groups according to their caffeine intake; Group 1: ≤150 mg/day, Group 2: 150-250 mg/day, and Group 3: ≥250 mg/day. Anthropometric measurements and biochemical parameters were recorded. Protein quantities in serum samples were determined by ELISA method.
Results: The body fat composition of group 1 was higher than group 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of group 3 were higher than group 1 and group 2, respectively. High-density lipoprotein cholesterol (HDL-C) level of group 3 was lower than group 1 and group 2. There was a positive correlation between total caffeine intake and ALT level. There was no significant difference between the caffeine intake groups in terms of serum protein levels. In addition, there was not found significant correlation between serum protein levels and total caffeine intake.
Conclusion: Caffeine intake of ≥250 mg/day may increase ALT and AST levels and decrease HDL-C level in individuals with NAFLD.
Anahtar Kelimeler
Non-alcoholic fatty liver disease, caffeine, alanine aminotransferase, aspartate aminotransferase, high-density lipoprotein
Kaynakça
- Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593-608.
- Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D et al. Nonalcoholic fatty liver disease: a multisystem disease? World J Gastroenterol. 2016;22:9488-505.
- Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34:1250-8.
- Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 2012;57:1090-6.
- Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:76-82.
- Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol. 2014;29:435-41.
- Feld JJ, Lavoie EG, Fausther M, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res. 2015;4:95.
- Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res 2015. 165:428-36.
- Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-36.
- Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51:201-9.
